Tradestie Institutional Equity Comparison Engine
IMVT vs MLTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IMVT Overall Edge
IMVT Captures Institutional Edge (2โ1 Pillars ยท 4โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immunovant, Inc. Common Stock (IMVT) driven by superior Momentum & Technical, Options & Structure while MLTX counters with relative strength in Growth & Margin. Fundamentally, IMVT trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MLTX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, IMVT sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against MLTX sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
IMVT N/M vs MLTX N/M Fwd P/E
Growth & Margin Winner
MLTX
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
IMVT
1Y +46.0% vs -5.7% ยท 52W Pos 49% vs 17%
Options & Structure Winner
IMVT
CONSOLIDATION (6th %ile IV) vs BREAKDOWN (7th %ile IV)
IMVT
NASDAQ
Immunovant, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$33.30
-2.56% 1D
Market Cap
$7.3B
1M Return
+24.6%
1Y Return
+45.95%
Forward P/E
N/M
Unified AI Score
39.6 / 100
SELL
Tech 15.0
Fund 36.0
Flow 68.0
Mom 50.0
MLTX
NASDAQ
MoonLake Immunotherapeutics Class A Ordinary Shares
Pharmaceutical Preparations
$11.85
-5.2% 1D
Market Cap
$1.1B
1M Return
+24.08%
1Y Return
-5.65%
Forward P/E
N/M
Unified AI Score
38.3 / 100
SELL
Tech 32.0
Fund 44.0
Flow 75.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
IMVT +45.95%
MLTX -5.65%
Spread: +51.6 pp (IMVT Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
IMVT TTM Op. Margin: 0.0%
MLTX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMVT vs MLTX. Trailing 12-month operating profitability (IMVT 0.0% vs MLTX 0.0%) and valuation multiples (IMVT N/M vs MLTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IMVT | MLTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $7.3B | $1.1B | Larger Scale | IMVT |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -86.5% | -81.5% | Higher ROE | MLTX |
| 52-Week Range Position Momentum | 49% ($22โ$45) | 17% ($9โ$23) | Stronger Trend | IMVT |
| Beta / 30D Volatility Risk Regime | 1.74ฮฒ ยท 72% Vol | 1.61ฮฒ ยท 90% Vol | Lower Realized Risk | IMVT |
| Unified Institutional Score Composite Signal | 39.6 / 100 (SELL) | 38.3 / 100 (SELL) | Higher Composite | IMVT |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full IMVT vs MLTX Buy Guide
IMVT
CONSOLIDATION
93d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
6th %ile
IV Regime
Compressed (<25th %ile)
MLTX
BREAKDOWN
103d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
7th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither IMVT nor MLTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.